<code id='16B8353E60'></code><style id='16B8353E60'></style>
    • <acronym id='16B8353E60'></acronym>
      <center id='16B8353E60'><center id='16B8353E60'><tfoot id='16B8353E60'></tfoot></center><abbr id='16B8353E60'><dir id='16B8353E60'><tfoot id='16B8353E60'></tfoot><noframes id='16B8353E60'>

    • <optgroup id='16B8353E60'><strike id='16B8353E60'><sup id='16B8353E60'></sup></strike><code id='16B8353E60'></code></optgroup>
        1. <b id='16B8353E60'><label id='16B8353E60'><select id='16B8353E60'><dt id='16B8353E60'><span id='16B8353E60'></span></dt></select></label></b><u id='16B8353E60'></u>
          <i id='16B8353E60'><strike id='16B8353E60'><tt id='16B8353E60'><pre id='16B8353E60'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:hotspot    Page View:39
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In